VGNX: Variagenics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VGNX: Variagenics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

From: Mike McFarland	2/23/2002 7:44:29 AM
	of 2

Notes from bio presentation: Richard Shea spoke. They have 135 employees now. LOH, SNP, Haplotypes, Gene Expression Profiling>>Prediction Pharma has not moved very fast into pharmacogenomics, getting royalties is something they are "working on", pretty vague. Diagnostic development program--Genematrix Vgnx assays and Nucleave at Covance Outlicensing validated markers Nanogen MTFHR marker 25 pathways...Candidate gene approach... Not going to do data subscription model VIP partners are Amgen and B.I.-- should be a strategic VIP partner in the area of oncology and other VIP partners in 2002 Should be a diagonstic collab in 2002--is this the Colorectal? There are three treatment options for Colorectal, so that is efficacy and toxicity times 3=6 tests. "A 200M market" Something about cardio and CNS academic proof of principal marker studies. My notes are very messy and the talk was a little muddled and seemed to jump around a lot, apologies. The audio player did not lauch any slides, don't think that there were any.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext